


Antibody Drug Conjugates


Sample payloads:

Focus Biomolecules can supply a variety of payload molecules for your ADC project. These can be supplied unmodified or derivatized to accommodate different conjugation strategies and chemistries. Possibilities include:


- Microtubule inhibitors (maytansinoids and auristatins)
- DNA-damaging agents
- RNA polymerase inhibitors



17-GMP-APA-Geldanamycin




Doxorubicin



Ansamitocin P3

Consisting of small molecule drugs covalently linked to antibodies, antibody drug conjugates (ADCs) are an exciting class of targeted therapies that offer the specificity of antibodies together with the potency of small molecule cytotoxic compounds. ADCs can deliver a toxic payload specifically to diseased cells or tissues, potentially allowing higher effective doses without harming healthy tissues. Although two ADCs are currently in use in the clinic [brentuximab vedotin (Adcetris) and ado-trastuzumab emtastine (Kadcyla)], further work is necessary to engineer optimal ADCs. In particular, finding ideal chemically labile linkers for ADCs that balance plasma stability with efficient drug release is an area of active investigation.

Focus Biomolecules can assist with both the supply of unmodified payload cytotoxins as well as derivatized versions to generate payloads for your research ADC. For example, the HSP90 inhibitor geldanamycin has been derivatized with a maleimido-side chain to allow generation of geldanamycin immunoconjugates:



17-GMP-APA-Geldanamycin (10-1324)

Contact us for a confidential consultation about your ADC project:

- Competitive quotes for your payload molecules
- Derivatization of your payload molecule to accommodate your conjugation strategy

sales@focusbiomolecules.com or 855-362-8721

References

1. Ducry and Stump *Bioconjugate Chem.* 2010 21:5
2. S. Panowski *et al. mAbs* 2014 6:34